GSK plc announced that on April 16, 2025, the US Advisory Committee on Immunization Practices recommended their RSV vaccine, Arexvy, for adults aged 50-59 at increased risk for severe RSV disease, potentially benefiting over 13 million individuals in the US, as RSV causes about 42,000 hospitalizations yearly in adults aged 50-64.